World's Most Common Painkiller During Pregnancy Linked to ADHD
Very few painkillers are safe to use during pregnancy, and yet one of the only available options has become embroiled in an international debate in recent years.
Acetaminophen, also known as paracetamol, is generally considered to be the safest painkiller to use during pregnancy, and yet emerging research that has linked the drug to attention deficit hyperactivity disorder (ADHD) suggests there may be overlooked risks to early brain development.
In a small new study, researchers in the United States tracked bloodstream levels of acetaminophen in 307 Black women during their pregnancy. They found those who used acetaminophen later gave birth to children more than three times as likely to receive an ADHD diagnosis.
For daughters, exposure to acetaminophen in the womb was linked to a more than six-fold increase in the risk of ADHD within the first ten years of life.
While that sounds concerning on the surface, these initial results are not conclusive and should not scare off the large percentage of people who rely on acetaminophen during pregnancy for pain or fever. Especially since robust evidence shows both of those symptoms can be threats to a developing fetus if left untreated.
As with any medicine, the benefits of acetaminophen must be balanced by the risks. Unlike its pros, however, the long-term cons are not as well researched.
"This medication was… approved decades ago, and may need reevaluation by the FDA," argues pediatrician Sheela Sathyanarayana from UW Medicine.
"Acetaminophen was never evaluated for fetal exposures in relation to long-term neurodevelopmental impacts."
In recent years, several other epidemiology studies have found associations between acetaminophen use during pregnancy and ADHD outcomes in children, and yet some studies have produced conflicting results. All of these investigations are purely correlational and their findings are not a cause for alarm, some scientists argue, but rather, alertness.
Because of the current study's small sample size, the data are probably not robust enough to change the minds of officials at the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the American College of Obstetricians and Gynecologists (ACOG), the Society of Obstetricians and Gynecologists of Canada, and the Society for Maternal-Fetal Medicine – all of whom maintain that acetaminophen poses minimal risk when using the lowest dose as needed during pregnancy.
For instance, the current study does not account for factors "like the mother's reason for taking [paracetamol], such as headaches or fevers or pains or infections, which we know are risk factors for adverse child development," statistical geneticist Viktor Ahlqvist from Sweden's Karolinska Institute, who was not involved in the current research, told Grace Wade at New Scientist.
Nevertheless, lead author Brennan Baker, from Seattle Children's Research Institute, thinks it may be time for the FDA to take another look at acetaminophen's safety during pregnancy.
The last time the FDA did so was in 2015, when officials declared there was inconclusive evidence to connect acetaminophen use in pregnancy and ADHD in children.
"Most of the prior studies asked women to self-report whether they had taken Tylenol or anything that contained acetaminophen," explains Baker.
In 2020, two studies (one led by Baker) measured acetaminophen levels in newborns and found that higher levels of the painkiller were linked with ADHD in childhood. One of these also found a link to autism spectrum disorder (ASD).
In light of this initial data, an international team of 91 scientists, clinicians, and public health professionals came together to urge 'precautionary action'.
"[Acetaminophen] is an important medication and alternatives for treatment of high fever and severe pain are limited," they wrote in a Consensus Statement for Nature Reviews Endocrinology in 2021.
"We recommend that pregnant women should be cautioned at the beginning of pregnancy to: forego acetaminophen unless its use is medically indicated; consult with a physician or pharmacist if they are uncertain whether use is indicated and before using on a long-term basis; and minimize exposure by using the lowest effective dose for the shortest possible time."
In response to the 2021 commentary, officials at ACOG held firm.
"Neurodevelopmental disorders, in particular, are multifactorial and very difficult to associate with a singular cause. The brain does not stop developing until at least 15 months of age, which leaves room for children to be exposed to a number of factors that could potentially lead to these issues," they wrote in 2021.
"ACOG's clinical guidance remains the same and physicians should not change clinical practice until definitive prospective research is done."
A study on 307 pregnant people that needs to be replicated again is probably not going to cut it.
"The conflicting results means that more research is needed," says Baker.
The study was published in Nature Mental Health.
Female Physicians Are Dying by Suicide at Astonishingly High Rates
Study Finds Humans Age Faster at 2 Sharp Peaks – Here's When
Extreme Heat Can Accelerate Aging, New Research Finds
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Refinery29
2 hours ago
- Refinery29
A new editorial destination dedicated to conversations and content about health and wellness issues of interest to Black women.
A new editorial destination dedicated to conversations and content about health and wellness issues of interest to Black women.
Yahoo
3 hours ago
- Yahoo
Health New England to replace Humira coverage with lower-cost biosimilars
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health plans. Markey playing defense against GOP clean energy plans Effective July 1, the not-for-profit health insurer will cover Amjevita by Nuvaila and Hadlima instead of Humira, as part of a broader effort to manage rising health care costs while maintaining access to effective treatments. Humira is used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. 'Biologic medications like Humira are complex treatments that carry significant cost. Its biosimilars provide a meaningful opportunity to enhance affordability for the health care ecosystem while members continue to get the full benefits of the medication,' said Gary Tereso, PharmD, Director of Pharmacy Services at Health New England. Biologic drugs are made from living organisms and are typically more expensive than other medications. Biosimilars are developed to be nearly identical in safety, potency, and efficacy to the original biologic, but at a significantly lower cost. The shift in coverage is intended to make treatment more accessible and financially sustainable for members and employer groups alike. Health New England is directly reaching out to members who are currently prescribed Humira, along with their health care providers and pharmacies, to assist with the transition. The company said it will continue monitoring the biosimilar marketplace to ensure members receive both high-quality care and cost-effective treatment options. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Medscape
4 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.